I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree, but there is one thing that Pluristem management could do if they really want to support shareholders...
Cancel the ATM agreement!!!
https://www.livemint.com/science/health/how-scientists-plan-to-use-stem-cell-therapy-to-treat-covid-19-patients-11587468318405.html
India has a bigger problem and big market.
The article is private but very reliable so I cannot post a link but I found this quote interesting...
"Those critics of the enthusiastic proclamations about HCQ point out that those studies cited in support of its effectiveness demonstrate limited benefit at best – somewhat faster recovery time, and some improvement in pneumonia symptoms, as compared with trial subjects not receiving HCQ. In particular, the patients in the study mostly had very mild cases of the coronavirus. This does not mean that the drug is useless – only that it’s not a panacea, as its most enthusiastic supporters appear to be claiming.
Dr Jeremy Faust, an emergency physician at Harvard Medical School and Brigham and Women’s Hospital in Boston, has warned against the notion of relying on HCQ as a preventive medication. He said, “Patients with lupus, arthritis, and other conditions are already on hydroxychloroquine. And we are diagnosing them with COVID 19 left and right!”
https://saraacarter.com/sens-cruz-coons-push-for-increased-us-israel-medical-partnership-to-combat-covid/
I'm going back into hibernation, got too much to do.
I think they already had access to PLX cells using them offlabel from a clinical trial.
Bill Gates can keep his vaccines... https://greatgameindia.com/bill-gates-agenda-in-india-exposed-by-robert-kennedy-jr/
Vaccines are not the solution... https://www.foxnews.com/science/significant-coronavirus-mutation-discovered-could-make-vaccine-search-futile
$PSTI on the this long list #62 (I'm glad we are on the shorter list of 7 in the EU consortium).
https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-14-20.pdf
Nice volume too
If you looking for a similar comparison, Celularity BUT they just stated phase 2 trials so $PSTI is way ahead in development, marketing and trials IMHO
Probably not but it confirms the proof of concept. $PSTI can deliver now and in quantity. If we have no side effects to speak of, nothing to say we cannot combine with IV vitamin C, hydroxychloroquine, Zpac azithromycin, or any number of other treatments. This virus has broken the mold for the big pharama racket. They can no longer monopolize who gets allowed into their club. Next thing you know you may see ALA IV for cancer.
More proof of concept...
https://www.ncbi.nlm.nih.gov/pubmed/32214286
"Pluristem currently carries a Zacks Rank #2 (Buy)."
Actually it means a lot even if nothing else happens (not my expectation).
1) It has increased the volume and exposure.
2) It has put the price above $5 so that funds could get involved.
3) It should have wiped out the ATM which has been a heavy weight on the share price for a long time. This should provide the funds needed to complete their first phase 3 trial without dragging the price down.
4) If the anecdotal news is mostly positive, it should make an easier funding path for ARDS trial.
$PSTI The force is strong with this one...
COVID-19
1. kENUP Foundation is currently supporting the following product developments, listed here in alphabetical order, all with the aim to reach patients during 2020:
ChAdOx1 nCoV-19
a replication-deficient simian adenoviral vector vaccine candidate ready for rapid clinical testing.
Under development by the European-based operations of Vaccitech Limited, Oxford and the University of Oxford, with initial vaccine manufacturing anticipated to take place at facilities in the UK and Italy.
COVAX
a measles vector vaccine candidate.
Under development by Themis Bioscience GmbH, Vienna, in cooperation with Institut Pasteur, Paris, with manufacturing anticipated to occur in Germany.
Hydroxychloroquine
repurposing of Hydroxychloroquine for COVID-19 prophylaxis to protect medical staff.
Under development by Pharmakina SA, Democratic Republic of Kongo, in cooperation with the Institute for Tropical Medicine, Travel Medicine, and Human Parasitology, Prof. Dr. Peter Kremsner, of Eberhard Karls Universität Tübingen.
mAbCo19
a therapeutic and prophylactic human monoclonal antibody candidate.
Under development by AchilleS Vaccines Srl Siena, in cooperation with the
laboratory of Dr. Rino Rappuoli, with manufacturing anticipated to occur in Italy
NVX-CoV2373
a RNV vaccine candidate.
Under development by Novavax Inc., and Novavax AB, Uppsala, with both antigen-manufacturing and adjuvant-manufacturing anticipated to occur in the EU.
plant-based protein production
a proprietary plant-based expression platform to mass-produce recombinant antigens and antibodies for use in diagnostics.
Under development by Cape Bio Pharms (Pty.) Ltd., Cape Town.
PLX-PAD
a cell therapy candidate for the treatment of severe pneumonia due to COVID-19.
Under development by Pluristem Ltd., Haifa, and Pluristem GmbH, Berlin.
VPM1002
usage of novel, recombinant BCG vaccine for the prevention of COVID-19 via the induction of trained immunity.
Under development by Serum Institute of India Pvt. Ltd., Bilthoven Biologicals B.V. and Vakzine Projekt Management GmbH (VPM), in cooperation with the Max Planck Institute for Infection Biology, Berlin.
Please dont hesitate to get back to us with any questions or comments you may have. The team can be reached at covid19@kenup.eu.
Last updated on April 9, 2020 at 07:30h
COVID-19 stem cell news $PSTI
Pluristem Changes the Game with Strong Preliminary COVID-19 Results; Analyst Says ‘Buy’
TipRanks•April 8, 2020
With the war against COVID-19 waging on, Wall Street focus has locked in on the names at the frontline. Battling a formidable opponent capable of spreading without a trace, innovative technologies will be required to arm the world’s population. As such, market watchers are standing at the ready, hoping to identify the healthcare companies that can deliver effective weapons against the deadly virus.
Pluristem Therapeutics (PSTI) has a fighting chance. On April 7, the company reported its treatment for acute respiratory failure and inflammatory complications caused by COVID-19 had demonstrated robust preliminary results from the compassionate use program, sending shares 21% higher in response. Back in March, its PLX cell treatment, which uses allogeneic mesenchymal-like cells with immunomodulatory properties, got the go ahead from the Israeli Ministry of Health for use in treating severe COVID-19 patients on a per-patient basis. The therapy was designed to prevent or even reverse the harmful over-activation of the immune system.
The results have been promising to say the least. Management stated that so far, seven patients in the ICU with Acute Respiratory Distress Syndrome (ARDS) have been treated. All of the patients are alive, meaning that the survival rate is 100%, and six out of seven have progressed through at least one week of follow-up. On top of this, four patients saw respiratory parameters improve, one remained stable and only one demonstrated deterioration. Three are also in the advanced stages of being taken off ventilators.
Weighing in for H.C. Wainwright, analyst Swayampakula Ramakanth calls the early data “encouraging” and thinks the treatment could drive substantial gains for PSTI, with the next step being a regulated and multinational clinical study.
“In our view, with the ongoing pandemic affecting nearly every country and stressing healthcare systems around the world, new, effective treatments are urgently needed. Therefore, we believe that both the FDA and the EMA may expedite the approval for clinical studies and simply the regulatory paths going forward. With regulatory expediency and patients only needing a 28-day follow-up, we believe the company could complete the initial studies and report results in 2H20,” Ramakanth explained.
In line with this optimistic take, Ramakanth left a Buy rating on the stock. At $15.50, the price target puts the upside potential at a whopping 277%. (To watch Ramakanth’s track record, click here)
As for other analyst activity, it has been relatively quiet when it comes to PSTI. Only one other call has been issued recently, but it was also bullish, so the analyst consensus is a Moderate Buy. The $11.75 average price target is less aggressive than Ramakanth’s and implies 173% upside potential. (See Pluristem stock analysis on TipRanks)
$PSTI Pluristem Changes the Game with Strong Preliminary COVID-19 Results; Analyst Says ‘Buy’
TipRanks•April 8, 2020
With the war against COVID-19 waging on, Wall Street focus has locked in on the names at the frontline. Battling a formidable opponent capable of spreading without a trace, innovative technologies will be required to arm the world’s population. As such, market watchers are standing at the ready, hoping to identify the healthcare companies that can deliver effective weapons against the deadly virus.
Pluristem Therapeutics (PSTI) has a fighting chance. On April 7, the company reported its treatment for acute respiratory failure and inflammatory complications caused by COVID-19 had demonstrated robust preliminary results from the compassionate use program, sending shares 21% higher in response. Back in March, its PLX cell treatment, which uses allogeneic mesenchymal-like cells with immunomodulatory properties, got the go ahead from the Israeli Ministry of Health for use in treating severe COVID-19 patients on a per-patient basis. The therapy was designed to prevent or even reverse the harmful over-activation of the immune system.
The results have been promising to say the least. Management stated that so far, seven patients in the ICU with Acute Respiratory Distress Syndrome (ARDS) have been treated. All of the patients are alive, meaning that the survival rate is 100%, and six out of seven have progressed through at least one week of follow-up. On top of this, four patients saw respiratory parameters improve, one remained stable and only one demonstrated deterioration. Three are also in the advanced stages of being taken off ventilators.
Weighing in for H.C. Wainwright, analyst Swayampakula Ramakanth calls the early data “encouraging” and thinks the treatment could drive substantial gains for PSTI, with the next step being a regulated and multinational clinical study.
“In our view, with the ongoing pandemic affecting nearly every country and stressing healthcare systems around the world, new, effective treatments are urgently needed. Therefore, we believe that both the FDA and the EMA may expedite the approval for clinical studies and simply the regulatory paths going forward. With regulatory expediency and patients only needing a 28-day follow-up, we believe the company could complete the initial studies and report results in 2H20,” Ramakanth explained.
In line with this optimistic take, Ramakanth left a Buy rating on the stock. At $15.50, the price target puts the upside potential at a whopping 277%. (To watch Ramakanth’s track record, click here)
As for other analyst activity, it has been relatively quiet when it comes to PSTI. Only one other call has been issued recently, but it was also bullish, so the analyst consensus is a Moderate Buy. The $11.75 average price target is less aggressive than Ramakanth’s and implies 173% upside potential. (See Pluristem stock analysis on TipRanks)
Why is this news not on all the news releases?
MOD - PSTI - could you please move this board to the "US listed" category.
Home > Boards > US OTC > Medical - Drugs >
Pluristem Therapeutics, Inc. (PSTI)
It has not been on the OTC for a sometime now. Google searches come up for ihub and it can make a difference on how the company is viewed.
Move to: Home > Boards > US Listed > Biotechs >
Thanks
MOD - NWBO - could you please move this board to the "US listed" category.
Home > Boards > US OTC > Medical - Drugs >
NorthWest Biotherapeutics (NWBO)
It has not been on the OTC for a sometime now. Google searches come up for ihub and it can make a difference on how the company is viewed.
Move to: Home > Boards > US Listed > Biotechs >
Thanks
I was one of the only longs that was happy with the 20 million stock offering. I like the technology and am still holding as tox will come and prices will rise again and I am not a day-trader but choose companies carefully and I will often sell some into unwarranted spikes. But to maximize shareholder value for everyone, they need to make all the companies involved with NNVC's success, "Walstreet Friendly". When you join the "Big Boys" club you need to understand the "rules" if you want to succeed.
Just announcing that they are "exploring the best way to merge the companies for maximum shareholder value" and then also addressing the easy to correct mis-information in the seeking alpha hack, could turn the sentiment positive while they hash out the details. IMHO
Just one more reason to not put all your eggs in one basket.
Stocks: Insiders Buy at Argos Therapeutics, Biolase, and El Paso Pipeline
http://www.minyanville.com/trading-and-investing/stocks/articles/Stocks-Insiders-Buy-at-Argos-Therapeutics/2/13/2014/id/53755?camp=syndication&medium=portals&from=yahoo